ESTRO 2024 - Abstract Book

S1950

Clinical - Mixed sites, palliation

ESTRO 2024

Results:

A total of 160 patients were included, of whom 106 were female (66.25%) and 54 male (33.75%), with a median age of 65 years (32-88 years). Primary tumors included lung cancer (41.25%), prostate cancer (14.38%), breast cancer (8.75%) and other primary (35.62%). Tumors were adenocarcinomas (58.13%), epidermoid (6.25%), undifferentiated carcinoma (5.63%) and other histologies (29.99%). Median follow-up was 18.57 months (0.03-95.37 months). Of the 160 patients, 34 had metastases at diagnosis (21.25%) and 71 had brain metastases at some time during their disease (44.38%). Median overall survival was 53.2 months (1-1,090 months). 45.6% died of the tumors, 33.7% are still alive (11.8% in complete remission), 11.25% died of another cause and 5.6% of patients were lost to follow-up. After application of the METABANK score, patients were classified into the 4 risk groups: 21 patients in the low-risk group (13.13%), 46 in the low-intermediate group (28.75%), 39 in the high-intermediate group (24.38%) and 54 in the high-risk group (33.75%). Median survival in the low-risk group was 26.27 months vs the 41.2 months predicted by the METABANK Score; 9 of the 21 patients in this group (42.8%) matched METABANK Score expectations. In the low intermediate risk group the median survival was 28.18 months vs. 29.3 months according to the METABANK Score; 24 of 46 (56.2%) patients matched the expected survival. In the high-intermediate risk group the median survival was 13.3 months vs. 17.4 months expected; 16 of the 39 patients (41%) matched the expected survival according to the METABANK score. Finally, the survival of the high-risk group was 13.3 months vs 7.9 months expected; 36 of the 54 patients (66.67%) matched the METABANK Score survival.

Conclusion:

The METABANK score is a tool to establish the prognosis of patients with oligometastases. In this study, applying the METABANK score to our population, limited predictive capacity was observed. Studies are needed to evaluate the combination with other clinical variables to improve the prediction of this score in our population.

Keywords: SBRT, oligometastases, METABANK Score, survival

References:

- Collen C, de Vin T, Defauw A, Dubaere E, Barbé K, De Ridder M. - Van den Begin R, Engels B, The METABANK score: A clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease. Radiother Oncol. 2019 Apr;133:113-119. doi: 10.1016/j.radonc.2019.01.001. Epub 2019 Jan 24. PMID: 30935566. - Collen C, Christian N, Schallier D, Meysman M, Duchateau M, Storme G, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol 2014;25:1954 – 9. https://doi.org/10.1093/annonc/mdu370. - Van den Begin R, Engels B, Boussaer M, Dhont J, Burghelea M, Depuydt T, et al. Motion management during SBRT for oligometastatic cancer: results of a prospective phase II trial. Radiother Oncol 2016;119:519 – 24. https://doi.org/ 10.1016/j.radonc.2016.04.020. - Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665 – 72. https://doi.org/10.1016/ S0140-6736(04)16250-8.